.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BA04_Elacestrant.Elacestrant .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BA04_Elacestrant.Elacestrant| name: | Elacestrant |
| ATC code: | L02BA04 | route: | oral |
| n-compartments | 2 |
Elacestrant is an orally bioavailable, nonsteroidal selective estrogen receptor degrader (SERD) used for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer. It is approved for clinical use in adults with ER+/HER2- breast cancer that has progressed after prior endocrine therapy.
Pharmacokinetics were evaluated in adult patients with advanced ER+/HER2- breast cancer receiving oral elacestrant as monotherapy.
Beumer, JH, & Foldi, J (2023). Pharmacology and pharmacokinetics of elacestrant. Cancer chemotherapy and pharmacology 92(2) 157–163. DOI:10.1007/s00280-023-04550-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37314500
Qureshi, Z, et al., & Shah, S (2024). Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review. Annals of medicine and surgery (2012) 86(8) 4624–4633. DOI:10.1097/MS9.0000000000002293 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39118705
Jager, A, et al., & Aftimos, P (2020). A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using . Breast cancer research : BCR 22(1) 97–None. DOI:10.1186/s13058-020-01333-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32912274